ReviewBMC cardiovascular disorders2020
Advances in transcatheter mitral and tricuspid therapies.
Review in BMC cardiovascular disorders, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 76 citations in OpenAlex.
- Morphological Variation in the Human Mitral Valve Using Statistical Shape Modelling.Annals of biomedical engineering · 2026Article
- Severe Aortic Stenosis Associated with Other Valve Diseases: Open Surgery or Percutaneous Treatment?Reviews in cardiovascular medicine · 2024Review
- Long-term outcomes and quality of life following implementation of dedicated mitral valve Heart Team decisions for patients with severe mitral valve regurgitation in tertiary cardiovascular care center.Cardiology journal · 2024Article
- Cardiac Surgery in Nonagenarians Following the TAVI/TMVI Era: A Multicenter 23-Year Comparative Analysis.Journal of clinical medicine · 2023Article
- Macrophages modulate stiffness-related foreign body responses through plasma membrane deformation.Proceedings of the National Academy of Sciences of the United States of America · 2023Article
- Smoking cessation interventions in South Asian Region: a systematic scoping review.BMC public health · 2022Article
- Transcatheter tricuspid valve intervention techniques and procedural steps for the treatment of tricuspid regurgitation: a review of the literature.Open heart · 2022Review
- Examining the forgotten valve: outcomes of tricuspid valve surgery, a 15-year experience.Irish journal of medical science · 2022Article
- Mutual Arrangements of Coronary Blood Vessels within the Right Atrial Appendage Vestibule.Journal of clinical medicine · 2021Article
- Innovative transcatheter procedures for the treatment of heart failure.Cardiovascular diagnosis and therapy · 2021Review
- The COVID-19 Pandemic Surge and Impact on Rheumatic Valvular Heart Disease Patient Care.Journal of the Saudi Heart Association · 2021Review
- Radiofrequency ablation alters the microstructural organization of healthy and enzymatically digested porcine mitral valves.Experimental mechanics · 2021Article
- Transcatheter Tricuspid Valve Therapy: From Anatomy to Intervention.Frontiers in cardiovascular medicine · 2021Review
- Patient with heart failure: importance to treat valvular diseases.European heart journal supplements : journal of the European Society of Cardiology · 2020Article
- Right-sided double valve replacement in an adult patient who underwent surgery for pulmonary stenosis in childhood: a case report.Journal of cardiothoracic surgery · 2020Article
- Interventional treatment of tricuspid regurgitation : An important innovation in cardiology.Wiener klinische Wochenschrift · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 6 institutions in 7 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWhile rheumatic mitral stenosis has been effectively treated percutaneously for more than 20 years, mitral and tricuspid regurgitation treatment appear as a contemporary unmet need. The advent of transcatheter therapies offer new treatment options to often elderly and frail patients at high risk for open surgery. We aimed at providing an updated review of fast-growing domain of transcatheter mitral and tricuspid technology. MAIN BODY: We reviewed the existing literature on mitral and tricuspid transcatheter therapies. Mitraclip is becoming an established therapy for secondary mitral regurgitation in selected patients with disproportionately severe regurgitation associated with moderate left ventricle dysfunction. Evidence is less convincing for primary mitral regurgitation. Transcatheter mitral valve replacement is a promising emerging alternative to transcatheter repair, for secondary as well as primary mitral regurgitation. But further development is needed to improve delivery. Transcatheter tricuspid intervention arrives late after similar technologies have been developed for aortic and mitral valves and is currently at its infancy. This is likely due in part to previously under-recognized impact of tricuspid regurgitation on patient outcomes. Edge-to-edge repair is the most advanced transcatheter solution in development. Data on tricuspid annuloplasty and replacement is limited, and more research is warranted.
conclusionThe future appears bright for transcatheter mitral therapies, albeit their place in clinical practice is yet to be clearly defined. Tricuspid transcatheter therapies might address the unmet need of tricuspid regurgitation treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.